Liabilities / Assets
52nd percentile
Higher debt load relative to assets than 52% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.08x
Liabilities / Revenue
52nd percentile
Higher debt load relative to revenue than 52% of similar nonprofits.
Net Margin
55th percentile
Higher net margin than 55% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
51st percentile
Faster asset growth than 51% of similar nonprofits.
Revenue Growth
59th percentile
Faster revenue growth than 59% of similar nonprofits.
Balance Sheet
Assets
Up$4,647,616
Up $212,456 (+4.8%) from 2022
Net Assets
Up$4,269,799
Up $294,720 (+7.4%) from 2022
Liabilities
Down$377,817
Down $82,264 (-18%) from 2022
Revenue And Expenses
Revenue
Up$3,705,576
Up $397,420 (+12%) from 2022
Expenses
Down$3,466,626
Down $56,954 (-1.6%) from 2022
Net Income
Up$238,950
Up $454,374 (+211%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
To provide a collaborative infrastructure to make progress in the prevention, diagnosis and treatment of sarcoma.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $4,647,616
- Liabilities
- $377,817
- Net assets
- $4,269,799
- Revenue
- $3,705,576
- Expenses
- $3,466,626
- Net income
- $238,950